Angion Biomedica Corp is a biopharmaceutical company focused on acute kidney injury, acute lung injury, and CNS injury. It focuses on the discovery, development, and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The company develops treatments for delayed graft function, cardiac surgery-associated acute kidney injury, anti-fibrotic (chronic kidney disease, IPF) indications, etc.